Affiliation:
1. Azienda Ospedaliero-Universitaria Policlinico ‘G. Rodolico – San Marco’, University of Catania, Catania, Italy
Abstract
AF is a highly prevalent disease, often requiring long-term oral anticoagulation to prevent stroke or systemic embolism. Coronary artery disease, which is common among AF patients, is often referred for myocardial revascularisation by percutaneous coronary intervention (PCI), which requires dual antiplatelet therapy to minimise the risk of stent-related complications. The overlap of AF and PCI is a clinical conundrum, especially in the early post-procedural period, when both long-term oral anticoagulation and dual antiplatelet therapy are theoretically indicated as a triple antithrombotic therapy. However, stacking drugs is not a desirable option because of the increased bleeding risk. Several strategies have been investigated to mitigate this concern, including shortening triple antithrombotic therapy duration and switching to a dual antithrombotic regimen. This review analyses the mechanisms underlying thrombotic complications in AF-PCI, summarises evidence surrounding antithrombotic therapy regimens and reports and comments on the latest European guidelines.
Publisher
Radcliffe Media Media Ltd
Subject
Cardiology and Cardiovascular Medicine
Reference94 articles.
1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics – 2018 update: a report from the American Heart Association. Circulation 2018;137:e67–e492. https://doi.org/10.1161/CIR.0000000000000558; PMID: 29386200.
2. Michniewicz E, Mlodawska E, Lopatowska P, et al. Patients with atrial fibrillation and coronary artery disease – double trouble. Adv Med Sci 2018;63:30–5. https://doi.org/10.1016/j.advms.2017.06.005; PMID: 28818746.
3. Hindricks G, Potpara T, Dagres N, et al. ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021;42:373–498. https://doi.org/10.1093/eurheartj/ehaa612; PMID: 32860505.
4. Calderone D, Greco A, Ingala S, et al. Efficacy and safety of aspirin for primary cardiovascular risk prevention in younger and older age: an updated systematic review and meta-analysis of 178,310 subjects from 21 randomized studies. Thromb Haemost 2022;122:445–55. https://doi.org/10.1055/a-1667-7427.
5. Capodanno D, Alfonso F, Levine GN, et al. Guidelines on dual antiplatelet therapy. J Am Coll Cardiol 2018;72:2915–31. https://doi.org/10.1016/j.jacc.2018.09.057; PMID: 30522654.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献